PATRICIA DAVIS
Nursing in Wilmington, DE
License number
Pennsylvania RN142995L
Category
Nursing
Type
Registered Nurse
Address
Address
2
Wilmington, DE 19809
Pennsylvania
Pennsylvania
Personal information
See more information about PATRICIA DAVIS at radaris.comName
Address
Phone
455 Nilan Hill Rd, Point Marion, PA 15474
4546 N Smedley St, Philadelphia, PA 19140
4640 Walnut St APT A6, Philadelphia, PA 19139
4470 Jasmine Dr, Bethlehem, PA 18020
4541 N Carlisle St, Philadelphia, PA 19140
Professional information
See more information about PATRICIA DAVIS at trustoria.com
Patricia Davis - Wilmington, DE
Patricia Davis - Wilmington, DE
Work:
martin honda svc dept
appt coordinator colonial school district - New Castle, DE
Food Service Worker/Cashier
appt coordinator colonial school district - New Castle, DE
Food Service Worker/Cashier
Education:
william penn high school - New Castle, DE
high school diploma in n/a
high school diploma in n/a
Method Of Treating Sleep Disorders
Method Of Treating Sleep Disorders
US Patent:
2011014, Jun 16, 2011
Filed:
Nov 8, 2010
Appl. No.:
12/941411
Inventors:
Patricia C. Davis - Wilmington DE, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Helen R. Winter - Wilmington DE, US
Raymond F. Suckow - West Patterson NJ, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Helen R. Winter - Wilmington DE, US
Raymond F. Suckow - West Patterson NJ, US
International Classification:
A61K 31/554, A61P 25/20, A61P 25/22
US Classification:
51421113
Abstract:
A method of treating at least one symptom or condition associated with but not limited to: Sleep Disorders including but not limited to 1) Dyssomnia Disorders including but not limited to: a) Primary inomnia, b) Primary Hypersomnia, and c) narcolepsy; and 2) Parasomnias Disorders including but not limited to a) Nightmare Disorder, Sleep Terror Disorder and Sleepwalking Disorder, comprising administering an effective amount of Formula Ior its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Method Of Treating Sleep Disorders
Method Of Treating Sleep Disorders
US Patent:
2006025, Nov 9, 2006
Filed:
Jan 6, 2006
Appl. No.:
11/327804
Inventors:
Patricia Davis - Wilmington DE, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/554
US Classification:
514211130
Abstract:
A method of treating at least one symptom or condition associated with but not limited to: Sleep Disorders including but not limited to 1) Dyssomnia Disorders including but not limited to: a) Primary inomnia, b) Primary Hypersomnia, and c) narcolepsy; and 2) Parasomnias Disorders including but not limited to a) Nightmare Disorder, Sleep Terror Disorder and Sleepwalking Disorder, comprising administering an effective amount of Formula I
or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Method Of Treating Schizophrenia And Other Disorders
Method Of Treating Schizophrenia And Other Disorders
US Patent:
2011014, Jun 16, 2011
Filed:
Nov 15, 2010
Appl. No.:
12/946425
Inventors:
Patricia C. Davis - Wilmington DE, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Helen R. Winter - Wilmington DE, US
Raymond F. Suckow - West Patterson NJ, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Helen R. Winter - Wilmington DE, US
Raymond F. Suckow - West Patterson NJ, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/554, A61P 25/18
US Classification:
51421113
Abstract:
A method of treating at least one symptom or condition associated with but not limited to: 1) Schizophrenia and other Psychotic Disorders including but not limited to Psychotic Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and Psychotic Disorder Due to a General Medical Condition and 2) Dementia and other Cognitive Disorders comprising administering an effective amount of Formula Ior its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Method Of Treating Mood Disorders
Method Of Treating Mood Disorders
US Patent:
2006021, Sep 28, 2006
Filed:
Jan 6, 2006
Appl. No.:
11/327636
Inventors:
Patricia Davis - Wilmington DE, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/553, A61K 31/554
US Classification:
514211120, 514211130
Abstract:
A method of treating at least one symptom or condition associated with but not limited to: Mood Disorders including but not limited to a) Depressive Disorders, including but not limited to Major Depressive Disorder and Dysthymic Disorder and b) Bipolar Depression and/or Bipolar mania including but not limited to Bipolar I Disorder, including but not limited to those with manic, depressive or mixed episodes, and Bipolar 11 Disorder, c) Cyclothymic Disorder, and d) Mood Disorder Due to a General Medical Condition comprising administering an effective amount of Formula I
or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Method Of Treating Anxiety Disorders
Method Of Treating Anxiety Disorders
US Patent:
2011013, Jun 9, 2011
Filed:
Nov 8, 2010
Appl. No.:
12/941239
Inventors:
Patricia C. Davis - Wilmington DE, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Helen R. Winter - Wilmington DE, US
Raymond F. Suckow - West Patterson NJ, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Helen R. Winter - Wilmington DE, US
Raymond F. Suckow - West Patterson NJ, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/554, A61P 25/22
US Classification:
51421111
Abstract:
A method of treating at least one symptom or condition associated with but not limited to: Anxiety Disorders including but not limited to Panic Disorder Without Agoraphobia, Panic Disorder With Agoraphobia, Agoraphobia Without History of Panic Disorder, Specific Phobia, Social Phobia, Obsessive-Compulsive Disorder, Postaumatic Stress Disorder, Acute Stress Disorder, Generalized Anxiety Disorder and Generalized Anxiety Disorder Due to a General Medical Condition comprising administering an effective amount of Formula Ior its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Method Of Treating Schizophrenia And Other Disorders
Method Of Treating Schizophrenia And Other Disorders
US Patent:
2006021, Sep 28, 2006
Filed:
Jan 6, 2006
Appl. No.:
11/327638
Inventors:
Patricia Davis - Wilmington DE, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/553, A61K 31/554
US Classification:
514211120, 514211130
Abstract:
A method of treating at least one symptom or condition associated with but not limited to: 1) Schizophrenia and other Psychotic Disorders including but not limited to Psychotic Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and Psychotic Disorder Due to a General Medical Condition and 2) Dementia and other Cognitive Disorders comprising administering an effective amount of Formula I
or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Methods Of Treating Anxiety And Mood Disorders
Methods Of Treating Anxiety And Mood Disorders
US Patent:
2009009, Apr 9, 2009
Filed:
Jun 13, 2008
Appl. No.:
12/139095
Inventors:
Patricia C. Davis - Wilmington DE, US
Jeffrey Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Raymond F. Suckow - West Paterson NJ, US
Helen R. Winter - Mystic CT, US
Jeffrey Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Raymond F. Suckow - West Paterson NJ, US
Helen R. Winter - Mystic CT, US
Assignee:
ASTRAZENECA AB - Sodertalje
International Classification:
A61K 31/554, A61P 25/22
US Classification:
51421113
Abstract:
Methods of treating at least one symptom or condition associated with Anxiety Disorders and/or Mood Disorders comprising administering an effective amount of a compound of Formula Ior its pharmaceutically acceptable salt are provided herein.
Method Of Treatment
Method Of Treatment
US Patent:
2007011, May 24, 2007
Filed:
Jan 6, 2006
Appl. No.:
11/327807
Inventors:
Patricia Davis - Wilmington DE, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Jeffrey Goldstein - Wilmington DE, US
Scott Grimm - Wilmington DE, US
Helen Winter - Wilmington DE, US
Raymond Suckow - West Patterson NJ, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/554
US Classification:
514211130
Abstract:
A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula I
or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
Compositions
Compositions
US Patent:
2009009, Apr 9, 2009
Filed:
Jun 13, 2008
Appl. No.:
12/139000
Inventors:
Patricia C. Davis - Wilmington DE, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Raymond F. Suckow - West Paterson NJ, US
Helen R. Winter - Mystic CT, US
Jeffrey M. Goldstein - Wilmington DE, US
Scott W. Grimm - Wilmington DE, US
Raymond F. Suckow - West Paterson NJ, US
Helen R. Winter - Mystic CT, US
Assignee:
AstraZeneca AB - Sodertalje
International Classification:
A61K 31/554
US Classification:
51421113
Abstract:
Pharmaceutical compositions, oral pharmaceutical compositions, and solid dosage forms comprising up to about 750 mg of 11-piperazin-1-yldibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent are provided.